Alpha Family Trust Makes New Investment in Johnson & Johnson $JNJ

Key Points

• Alpha Family Trust acquired 3,225 shares of Johnson & Johnson for approximately $535,000 in the first quarter, signaling confidence in the company's stock.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, surpassing analyst estimates by $0.09, with revenue reaching $23.74 billion.
• The company declared a quarterly dividend of $1.30, which represents a 2.9% yield and a payout ratio of 55.61%.

Alpha Family Trust bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,225 shares of the company's stock, valued at approximately $535,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Watts Gwilliam & Co. LLC lifted its stake in Johnson & Johnson by 1.2% in the 1st quarter. Watts Gwilliam & Co. LLC now owns 6,720 shares of the company's stock worth $1,114,000 after purchasing an additional 82 shares in the last quarter. Aviso Financial Inc. increased its holdings in shares of Johnson & Johnson by 13.3% in the first quarter. Aviso Financial Inc. now owns 29,474 shares of the company's stock worth $4,888,000 after purchasing an additional 3,468 shares during the last quarter. Granite Harbor Advisors Inc. increased its holdings in shares of Johnson & Johnson by 7.7% in the first quarter. Granite Harbor Advisors Inc. now owns 9,789 shares of the company's stock worth $1,623,000 after purchasing an additional 701 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after acquiring an additional 130,645 shares in the last quarter. Finally, Brooklyn Investment Group boosted its position in shares of Johnson & Johnson by 22.6% during the 1st quarter. Brooklyn Investment Group now owns 20,173 shares of the company's stock valued at $3,345,000 after acquiring an additional 3,716 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.4%

Shares of JNJ stock traded up $0.7890 on Wednesday, reaching $178.5890. 9,028,878 shares of the company's stock were exchanged, compared to its average volume of 9,045,183. The company's fifty day simple moving average is $162.13 and its 200 day simple moving average is $158.73. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $180.61. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $430.10 billion, a PE ratio of 19.10, a P/E/G ratio of 2.24 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm posted $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JNJ shares. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.